| DIRECT COMPETITOR COMPARISON | |
| VNDA | LLY | JNJ | PFE | Industry | | Market Cap: | 319.34M | 42.96B | 177.58B | 149.21B | 98.96M | | Employees: | 24 | 40,500 | 118,700 | 81,800 | 65 | | Qtrly Rev Growth (yoy): | N/A | 6.80% | -5.30% | -2.90% | 19.70% | | Revenue (ttm): | N/A | 21.11B | 60.53B | 45.82B | 14.01M | | Gross Margin (ttm): | N/A | 82.33% | 71.08% | 86.61% | 65.68% | | EBITDA (ttm): | -31.67M | 7.74B | 19.05B | 21.31B | -12.30M | | Oper Margins (ttm): | N/A | 30.97% | 26.94% | 37.42% | -137.11% | | Net Income (ttm): | -34.13M | -216.00M | 12.77B | 8.09B | N/A | | EPS (ttm): | -1.271 | -0.197 | 4.579 | 1.204 | -0.31 | | P/E (ttm): | N/A | N/A | 14.06 | 15.36 | 17.26 | | PEG (5 yr expected): | N/A | 4.05 | 1.89 | 5.95 | 1.28 | | P/S (ttm): | N/A | 2.04 | 2.92 | 3.28 | 9.45 |
|
| LLY = Eli Lilly & Co. | | JNJ = Johnson & Johnson | | PFE = Pfizer Inc. | | Industry = Biotechnology | |
| BIOTECHNOLOGY COMPANIES RANKED BY SALES | |
|
| Company | Symbol | Price | Change | Market Cap | P/E | | Amgen Inc. | AMGN | 56.85 | 0.53% | 57.54B | 12.40 | | Genentech, Inc. | Private - View Profile | | Biogen Idec Inc. | BIIB | 48.18 | 1.69% | 13.93B | 16.12 | | Genzyme Corp. | GENZ | 49.98 | -0.58% | 13.26B | 28.49 | | Merck Serono S.A. | Private - View Profile | | Chiron Corporation | Private - View Profile | | Gilead Sciences Inc. | GILD | 46.59 | 0.71% | 41.93B | 18.02 | | MedImmune, Inc. | Private - View Profile | | Life Technologies Corporation | LIFE | 50.64 | 0.78% | 9.03B | 1033.47 | | Teva Pharmaceutical Industries Limited | TEVA | 54.01 | 0.82% | 47.58B | 49.41 |
|
| GENERIC DRUGMAKERS RANKED BY SALES | |
|
| Company | Symbol | Price | Change | Market Cap | P/E | | Sandoz International GmbH | Private - View Profile | | Watson Pharmaceuticals Inc. | WPI | 37.90 | 1.64% | 4.02B | 19.54 | | King Pharmaceuticals Inc. | KG | 11.72 | 0.43% | 2.91B | N/A | | Ranbaxy Laboratories Limited | Private - View Profile | | Mylan, Inc. | MYL | 17.99 | -1.15% | 5.50B | 110.37 | | Pfizer Inc. | PFE | 18.49 | -0.80% | 149.21B | 15.36 | | Johnson & Johnson | JNJ | 64.36 | 0.31% | 177.58B | 14.06 | | GlaxoSmithKline plc | GSK | 42.75 | 0.73% | 108.37B | 13.49 | | Sanofi-Aventis | SNY | 39.38 | -0.35% | 102.83B | N/A | | Novartis AG | NVS | 55.55 | -0.41% | 126.17B | 16.63 |
|
| DRUGMAKERS RANKED BY SALES | |
|
| Company | Symbol | Price | Change | Market Cap | P/E | | RHHBY.PK | 41.42 | -1.03% | N/A | N/A | | AstraZeneca plc | AZN | 46.30 | 1.49% | 67.13B | 9.30 | | Abbott Laboratories | ABT | 53.78 | -0.85% | 83.18B | 14.57 | | Bristol-Myers Squibb Co. | BMY | 25.14 | -0.08% | 49.80B | 13.01 |
|
| NEWS ON DIRECT COMPETITORS | |
| • | JNJ | | The Motley Fool's Weekly Editors' Picks
Sat 8:05am -
at Motley Fool | | • | JNJ | | Gold Diggers of '09, Beware
Sat 7:37am -
at Barrons.com | | • | LLY | | UPDATE - Bristol, Pfizer to seek apixaban approval
Fri, Dec 4 -
at Reuters | | • | LLY | | [video] Six Banks Are Shut Down
Fri, Dec 4 -
at Forbes.com | | • | PFE | | ADDING MULTIMEDIA Bristol-Myers Squibb And Pfizer Announce Plans To Submit Regulatory Filing For Apixaban In Europe
Fri, Dec 4 -
Business Wire | | • | JNJ | | UPDATE - FDA staff urge review of psychiatric drugs in kids
Fri, Dec 4 -
at Reuters | | • | JNJ | | Business Highlights
Fri, Dec 4 -
AP | | • | JNJ | | Antipsychotics, Diabetes & Kids
Fri, Dec 4 -
at The Wall Street Journal Online | | • | LLY | | FDA approves Lilly antipsychotic for teens
Fri, Dec 4 -
AP | | • | JNJ | | US FDA seeks plan to curb opioid pain killer abuse
Fri, Dec 4 -
at Reuters | | • | LLY | | FDA Approves Lilly's Zyprexa for Two Adolescent Indications
Fri, Dec 4 -
PR Newswire | | • | PFE | | After Rising 500%, What Did You Expect?
Fri, Dec 4 -
at Motley Fool | | • | PFE | | Ratiopharm gets higher offers, to winnow bidders
Fri, Dec 4 -
at Reuters | | | All Headlines for these symbols... |
|
|
|
0.22% Nasdaq 
Competitors
